The GoBroad medical team is among the first in China to carry out immunotherapy,partnering with enterprises to pioneer the use of novel second-generation CD19-41BB-CAR-T cell therapy for treating refractory relapsed acute B lymphoblastic leukemia.Subsequently,the team co-developed multiple targeted CAR-T therapies for hematologic malignancies.Their research findings have been presented at international academic conferences such as ASH,EHA,and EBMT,sharing China's explorations and experiences with the world.

• CD19 CAR-T therapy for R/R B-ALL achieved a complete remission(CR)rate of over 90%.

• CD22 CAR-T therapy for adult R/R B-ALL,with 78.9%achieving CR with incomplete platelet recovery(CRi),and CD22 CAR-T cell therapy followed by bridging to transplantation allowed CR patients to achieve a sustained remission of 4-39.7 months.

• Sequential CD19-22 CAR-T therapy for post-transplant relapsed B-ALL,with 23 out of 27 patients(85%)achieving CR after the first CD19 CAR-T infusion;21 of these patients received a second CD22 CAR-T,with a median follow-up of 19.7 months(5.6-27.3 months),14 patients remained in CR.The overall survival(OS)rate and event-free survival(EFS)rate at 12 and 18 months were 88.5%and 67.5%,respectively.

• Humanized CD19 CAR-T therapy for murine CD19 CAR-T relapsed or refractory R/R B-ALL,with a remission rate of 68%,and humanized CD19 CAR-T therapy followed by bridging transplantation allowed bridged transplant patients to achieve longer-term disease remission.

• The team administered obinutuzumab treatment to R/R B-ALL patients who relapsed or failed after CAR-T therapy,or who were unable to receive CAR-T treatment,with 66.7%of patients achieving CR.

• The team used blinatumomab for salvage treatment of R/R B-ALL patients who were refractory to or relapsed after CAR-T therapy,with 70%of patients reaching FCM-MRD negativity.